DAFNA Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

DAFNA Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21M	Sell	978,463 -20,700	-2%	-$292K	4.77%	4
2025 Q4	$9.31M	Hold	999,163	–	–	2.16%	13
2025 Q3	$7.04M	Buy	999,163 +120,000	+14%	+$826K	1.74%	14
2025 Q2	$5.71M	Buy	879,163 +147,800	+20%	+$1.02M	1.58%	16
2025 Q1	$5.8M	Hold	731,363	–	–	1.64%	16
2024 Q4	$9.27M	Sell	731,363 -19,000	-3%	-$264K	2.36%	14
2024 Q3	$10.5M	Buy	750,363 +83,900	+13%	+$1.2M	2.47%	13
2024 Q2	$9.18M	Hold	666,463	–	–	2.19%	16
2024 Q1	$11M	Sell	666,463 -20,000	-3%	-$299K	2.51%	12
2023 Q4	$10M	Buy	686,463 +100,000	+17%	+$1.21M	2.4%	13
2023 Q3	$7.2M	Buy	586,463 +79,363	+16%	+$1.04M	2.24%	13
2023 Q2	$6.05M	Buy	+507,100	New	+$6.62M	1.66%	19

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

DAFNA Capital Management's DAWN Position: Q1 2026 in Review

DAFNA Capital Management reduced its Day One Biopharmaceuticals (DAWN) stake by 2.1% in Q1 2026, selling an estimated $292K and leaving 978,463 shares worth $21M. The position accounts for 4.77% of the portfolio, ranked #4.

DAFNA Capital Management first reported a position in DAWN in Q2 2023 and has held it in 12 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

DAFNA Capital Management held 978,463 shares of Day One Biopharmaceuticals worth $21M as of Q1 2026.
DAFNA Capital Management sold 20,700 Day One Biopharmaceuticals shares in Q1 2026, an estimated $292K.
Day One Biopharmaceuticals made up 4.77% of DAFNA Capital Management's portfolio in Q1 2026, its #4 holding.
DAFNA Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and has held it in 12 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.